# oncology

About 24 search results

Sort by Date

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

Shanghai SinoUnited Hospital Announced Availability of World's First CAR-T Therapy for Solid Tumors in Advanced Gastric Cancer

EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

World's First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide

Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

Pope Leo XIV embraces paediatric patients at CNAO in Pavia

Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Pantai Hospital Kuala Lumpur Launches AI-Powered Adaptive Radiotherapy System to Advance Personalised Cancer Care in Malaysia

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

About Storm Media

The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.

The Storm Media (Chinese)

The Storm Media Japan

The Journalist

1% STYLE

Neihu District, Ruiguang Road, Lane 513, No. 37, 4F. Taipei, 114.

Stay True・Look Beyond

Version: 20260901-080217